You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

1598 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Polatuzumab Vedotin with Rituximab (Biosimilar IV and Rituximab SC) – In Combination with Chemotherapy for Previously Untreated LBCL
New Drug Funding Program
    Polatuzumab Vedotin with Rituximab (Biosimilar IV and Rituximab SC) – In Combination with Chemotherapy for Previously Untreated LBCL
New Drug Funding Program
    Polatuzumab Vedotin with Rituximab (Biosimilar IV and Rituximab SC) – In Combination with Chemotherapy for Previously Untreated LBCL
Updated
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
ODB - General Benefit
    dexamethasone
Updated
Mar 2026

Pages